Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Arguably the MYC activity gain is the most constantly observed phenomenon (>70% of cases) in transformed FL/MALT/CLL (Richter's transformation) and co-occurs with specific aberrations such as the loss of p53, CDKN2A/B, or gain of BCL2/BCL6.
|
31631728 |
2020 |
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, either DLBCL or FL can give rise to aggressive double-hit lymphomas (DHL) with concurrent activation of MYC and BCL2.
|
30874346 |
2019 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This paper describes how we discovered the juxtaposition of the MYC gene to the human immunoglobulin loci and how that finding was extended to characterize molecularly the t(14;18) chromosome translocation of follicular lymphoma and to clone the BCL2 gene.
|
28653191 |
2019 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We showed that DLBCL with MYC/BCL2-DH, and those with BCL2 translocation, harbour the characteristic mutation signatures that are associated with follicular lymphoma and its high-grade transformation.
|
31844144 |
2019 |
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our analysis provided a novel look on the transition range between FL and DLBCL, on DLBCL with poor prognosis showing expression patterns resembling that of Burkitt's lymphoma and particularly on 'double-hit' MYC and BCL2 transformed lymphomas.
|
31039827 |
2019 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To clarify the characteristics of double-hit follicular lymphomas, we analyzed 10 cases of double-hit follicular lymphomas and 15 cases of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements for clinicopathological and genome-wide copy-number alterations and copy-neutral loss-of-heterozygosity profiles.
|
28984304 |
2018 |
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We focused on one of these miRNAs, namely <i>miR-150</i>, which was uniformly downmodulated in all examined tFLs (∼3.5-fold), and observed that high levels of MYC are responsible for repressing <i>miR-150</i> in tFL by binding in its upstream region.
|
30213873 |
2018 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most common scenario is transformation of follicular lymphoma to either diffuse large B-cell lymphoma or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations; however, other indolent subtypes such as marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, or even nodular lymphocyte predominant Hodgkin lymphoma, can undergo similar histologic transformation.
|
30213394 |
2018 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fluorescence in situ hybridization (FISH) identified an IGH-BCL2 rearrangement in both the FL and high-grade B-cell components while a MYC rearrangement was detected in the high-grade B-cell component alone.
|
29793519 |
2018 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH.
|
29310838 |
2018 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oligonucleotide sets that probe breakpoints of <i>IGH-BCL2</i> (immunoglobulin heavy-apoptosis regulator) in follicular lymphoma (FL), <i>MYC-IGH</i> (MYC proto-oncogene, bHLH transcription factor-immunoglobulin heavy) in Burkitt lymphoma (BL) and <i>BCR-ABL1</i> (RhoGEF and GTPase activating protein-ABL proto-oncogene 1, non-receptor tyrosine kinase) in chronic myelogenous leukemia (CML) were designed.
|
28515100 |
2017 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MYC breaks (MYC-R) were detected in eight of 21 (38%) tFLs analysed by fluorescence in-situ hybridization (FISH), with a median MYC score of 86%.
|
28730642 |
2017 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC/BCL2 double hit lymphoma (DHL) has been the subject of many studies; however, no study has systemically compared the clinicopathologic features and prognostic factors between patients with de novo disease versus those with a history of follicular lymphoma (FL).
|
27203548 |
2016 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Follicular lymphoma with MYC and BCL2 translocations, so-called double-hit follicular lymphoma (DH-FL), is rare.
|
27544800 |
2016 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our limited experience showed that additional copy of intact MYC may be equivalent to "classic" DHL on the background of DLBCL with additional cytogenetic abnormalities, however isolated t(14;18)(q32;q21) translocation in combination with additional copy of intact MYC may demonstrate histology and clinical outcome more comparable with "classic" low grade follicular lymphoma, albeit with more aggressive morphology.
|
26464726 |
2015 |
Lymphoma, Follicular
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The detection of MYC protein expression in FL using IHC might be useful to predict more aggressive clinical course.
|
26261669 |
2015 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in epigenetic modifiers and antiapoptotic genes are introduced early in the common precursor, whereas tFL is specifically associated with alterations deregulating cell-cycle progression and DNA damage responses (CDKN2A/B, MYC, and TP53) as well as aberrant somatic hypermutation.
|
24388756 |
2014 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We detected EZH2 mutations in 12/55 (22%) follicular lymphomas (FL), 5/35 (14%) diffuse large B cell lymphomas with a germinal center immunophenotype (GCB-DLBCL), and 2/11 (18%) high grade B cell lymphomas with concurrent rearrangements of BCL2 and MYC.
|
22194861 |
2011 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, FISH and molecular genetic study confirmed concomitant MYC translocations and t(14;18) in the high-grade component, thereby suggesting the transformation of atypical Burkitt's lymphoma from an undiagnosed antecedent follicular lymphoma.
|
21736761 |
2011 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-MYC rearrangements are common in FL-BT and may play a role in the progression from FL to FL-BT or the poor clinical outcomes observed.
|
21286717 |
2011 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Transformation of follicular lymphoma to plasmablastic lymphoma with c-myc gene rearrangement.
|
21088162 |
2010 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Transformation from follicular lymphoma to high-grade B-cell lymphoma/leukemia with additional t(2;8)(p12;q24), with inverse expressions of c-MYC and BCL-2, and light-chain switch.
|
19351371 |
2009 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
Occurrence of ASHM in PIM-1, RhoH/TTF, and c-MYC was a constant finding in follicular lymphoma (FL) (all of 11 cases) but not so frequent in diffuse large B-cell lymphoma (DLBCL) (4 (33.3%) of 12 cases) and Marginal zone B-cell lymphoma (MZBCL) (1 (10.0%) of 10 cases).
|
19019431 |
2009 |
Lymphoma, Follicular
|
0.100 |
Biomarker
|
disease |
BEFREE |
BCL2(+)/MYC(+) lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1).
|
19597184 |
2009 |
Lymphoma, Follicular
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This is a small series but one which raises the possibility that the presence of a C-MYC translocations at presentation may identify a particularly aggressive subtype of FL.
|
18297523 |
2008 |